Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing–and exciting–development of antibody-drug conjugates (ADCs).
Whether you are an oncologist seeking information for your patients or a researcher with advanced knowledge of ADCs, our goal is to serve your needs–the needs of a diverse community of individuals involved in the field of ADC development, from basic research to clinical application. While we don’t pretend to be your single source of information, we expect that the journal will become one of your valuable, trusted and relevant resources.
Community of experts
Our new publication offers a digest of ongoing and breaking news and information, peer-reviewed studies and educational materials, monthly expert insight and opinion, CME alerts and expert coverage/reviews of leading conferences, and meetings from our specialized editors and guest physicians/researchers. Furthermore, we provide a peer-to-peer social media shell and blog section, designed to create a real community of experts for experts.
The inaugural journal presents the culmination of many months of research and carefully selected content designed to stimulate new and unexpected thoughts that will hopefully lead to a better understanding of the chemistry and clinical application of ADCs.
A pleasure and honor
As publisher, it’s my pleasure and honor to be part of this new journal, which is supported by a qualified team of medical and science writers, copy editors, designers and programmers. It’s also an honor to be working with an excellent team of editorial advisers and reviewers. I’m pleased to be working with our advertisers and sponsors since without their trust and support, the realization of this publication would not have been possible. Last but not least, I’m excited about the opportunity to be working with you, our readers and community members.
The long road to approval
In our first editorial (link), we write about the long and sometimes arduous road that the researchers and clinicians working on ADCs have traveled, from basic research to bedside, addressing both the failures and the successes. The excitement caused by new types of conjugate drugs entering the development pipeline is also discussed.
Developing clinically approved ADCs has indeed taken a long time. But with the approvals of Seattle Genetics’ brentuximab vedotin (Adceris®/SGN-35) in early 2011 and ado-trastuzumab emtansine (Kadcyla™; Genentech/Roche) in spring 2013, experts enthusiastically agree that these two new drugs will revolutionize the treatment of cancer. With another 50 ADC-based compounds currently in clinical trials, the two ground-breaking ADCs represent the first ripples of an unprecedented wave of new therapies likely to be approved in the coming years.
ADC Review/Journal of Antibody-Drug Conjugates is designed to appeal to a large audience of biomedical researchers and people from universities and commercial life science, clinical research, and pharmaceutical manufacturers, along with specialized physicians/oncologists, regulatory/government authorities and representatives from payers and policymakers.
A call for collaboration
We’ve entered a new era. The mission of ADC Review/Journal of Antibody-Drug Conjugates is to bring together the latest, peer-reviewed research studies, trial data and review articles about ADCs–from preclinical to Phase III and beyond. It’s about sharing knowledge, concepts and ideas to help advance the various technologies required to create much needed therapies long before they enter into clinical trials.
But it’s also about people like you. People empowered by an amazing community of individuals working together, willing to collaborate and prepared to share their advanced knowledge.
We can’t create a community of specialists by ourselves. Only with your help will we create a broad and thriving community that, in its own right, addresses the unique challenges in developing ADCs. That’s why we’re interested in your manuscripts, articles, meeting reports, blogs, letters to the editor and PowerPoint presentations. We want to hear your opinions and benefit from your expertise. That’s why we call on you to join us today. We truly believe it’s worth your time and effort.
June 1, 2013 | Peter Hofland, Ph.D | Executive Editor and Publisher | doi: 10.14229/jadc.2013.6.1.002
Received May 10, 2013 | Accepted May 29, 2013 | Published online June 1, 2013
